Tamoxifen use was associated with an approximately 4-fold higher risk of developing endometrial cancer, even after controlling for several confounding factors, including age, BMI, diabetes, hypertension, dyslipidemia, PCOS, and GnRH agonist treatment. Here, GNRH1 is linked to diabetes mellitus.